NCT07400029

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

A Phase II Trial of Obecabtagene Autoleucel Consolidation in Adult Patients With Acute Lymphoblastic Leukemia in First Complete Remission Without Measurable Residual Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).

Conditions

• Acute Lymphoblastic Leukemia

Interventions

Type	Name	Description
DRUG	Obecabtagene Autoleucel	Given as infusion. Obe-cel dose 1: Obe-cel will be administered 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy, allowing a minimum of 48 hour washout from the last dose of lymphodepleting chemotherapy.

Timeline

• Start date: 2026-02-03
• Primary completion: 2029-02-01
• Completion: 2029-02-01
• First posted: 2026-02-10
• Last updated: 2026-03-24

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study